Amarin's Litigation Landscape: Mostly Successful, Clearing The Field For A DecadeSeeking Alpha • 12/10/19
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® StudyGlobeNewsWire • 12/02/19
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific SessionsGlobeNewsWire • 11/18/19